Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change? by O. V. Averkov, V. I. Vechorko

Get full text

MODERN APPROACHES TO ANTICOAGULANT THERAPY OF PULMONARY EMBOLISM: FOCUS ON RIVAROXABAN by O. V. Averkov, V. I. Vechorko

Get full text

Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients by O. V. Averkov, V. I. Vechorko

Get full text

New SARS-CoV-2 Omicron variant — clinical picture, treatment, prevention (literature review) by V. I. Vechorko, O. V. Averkov, A. A. Zimin

Get full text

Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism by O. V. Averkov, V. I. Vechorko, O. A. Shapsigova

Get full text

NEWS2, 4C Mortality Score, COVID-GRAM, Sequential Organ Failure Assessment Quick scales as outcomes assessment tools for severe COVID-19 (pilot retrospective cohort study) by V. I. Vechorko, O. V. Averkov, D. V. Grishin, A. A. Zimin

Get full text

LIFE QUALITY IN ONE YEAR AFTER MYOCARDIAL INFRACTION WITH INCOPLETE REVASCULARIZATION by A. S. Semiokhina, E. O. Taratukhin, N. L. Bayandin, I. G. Gordeev, V. I. Vechorko

Get full text

COVID-19 infection after recent heart transplantation: a case report by V. I. Vechorko, I. G. Gordeev, E. V. Gubareva, E. V. Ryndyaeva, O. V. Averkov

Get full text

MALIGNANT HYPERTENSION WITH PREDOMINANT KIDNEY DAMAGE by N. D. Lapochkina, S. S. Mamedguseyinova, L. V. Korsakova, V. I. Vechorko, S. M. Otarova, I. G. Gordeev

Get full text

Factors and mechanisms of arterial hypertension development in patients with atherosclerosis of lower limb arteries by E. M. Evsikov, V. I. Vechorko, N. V. Teplova, M. H. Zhapueva, N. G. Artamonova

Get full text

Pulmonary Sequelae of COVID-19 in Patients With Lung Damage Over 75% (CT-4) by K. V. Komissarova, A. V. Godzenko, D. A. Doroshenko, I. G. Gordeev, O. V. Averkov, V. I. Vechorko

Get full text

The Effect of Carriage of <i>CYP3A5*3</i> and <i>CYP3A4*22</i> Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19 by I. I. TEMIRBULATOV, A. V. KRYUKOV, K. B. MIRZAEV, N. P. DENISENKO, S. P. ABDULLAEV, A. S. ZHIRYAKOVA, Y. V. SHEVCHUK, V. I. VECHORKO, O. V. AVERKOV, D. A. SYCHEV

Get full text

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study by Yu. V. Shevchuk, A. V. Kryukov, I. I. Temirbulatov, I. V. Sychev, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev

Get full text

A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir by Yu. V. Shevchuk, I. V. Sychev, A. V. Kryukov, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev

Get full text

Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review by A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, S. V. Glagolev, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, D. A. Sychev

Get full text

Predicting the risk of developing drug-induced liver injury during remdesivir therapy in COVID-19 patients using machine learning by Yu. V. Shevchuk, I. I. Shamigulov, I. V. Sychev, A. V. Kryukov, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev

Get full text